News

New Atlas11d
Non-surgical treatment eases chronic back pain & restores function
Clinical trials of a new, minimally invasive treatment for degenerated spinal discs have produced impressive results, significantly reducing back pain severity and improving function. It could mean ...
Knowridge Science Report7d
New injection could offer chronic low back pain relief
A new study sponsored by VIVEX Biologics, Inc. has shown promising results for patients suffering from chronic lumbar ...
Minimally invasive disc injection reduces pain and improves function in chronic back pain, feasibility study finds
VIVEX Biologics, Inc. sponsored research reports positive outcomes for patients with chronic lumbar discogenic pain treated ...
Physician's Weekly5d
Allogeneic NP Injection Reduces Chronic Lumbar Discogenic Pain, Boosts Function
A single intradiscal injection of allogeneic NP reduced chronic lumbar discogenic pain and improved function at 12 months, ...
Physician's Weekly13d
Who benefits from home-based exercise for adult spinal deformity? A prospective multicenter study on clinical and radiographic predictors.
The prevalence of adult spinal deformity (ASD) is expected to exceed 60 million by 2050 due to an aging population and increased life expectancy. Despite advances in surgery, high complication rates ...
BioRestorative Therapies Reports First Quarter 2025 Financial Results and Provides Business Update
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator ...
Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data
Detailed price information for Biorestorative Therapies Inc (BRTX-Q) from The Globe and Mail including charting and trades.
BioRestorative Therapies, Inc: Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data
BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on ...